Skip to main content

Table 2 Patient characteristics and the prevalence of DTC and apoptotic (M30-positive) tumor cells

From: The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy

 

DTC

Apoptotic tumor cells

 

n/total (%)

Pvalue

n/total (%)

Pvalue

Total

167/400 (42)

 

89/308 (29)

 

Menopausal status

    

   Premenopausal

100/229 (44)

 

54/176 (31)

 

   Postmenopausal

67/171 (39)

0.368

35/132 (27)

0.425

Histology

    

   Invasive ductal

130/324 (40)

 

81/258 (31)

 

   Invasive lobular

32/66 (49)

 

7/44(16)

 

   Other

2/6 (33)

 

0/3 (0)

 

   Missing

3/4 (75)

0.418d

1/3 (33)

0.060d

Tumor grade

    

   Grade 2

105/260 (40)

 

51/197 (26)

 

   Grade 3

56/120 (47)

 

32/94 (34)

 

   Missing

6/20 (30)

0.249d

6/17 (35)

0.150d

Tumor size before NACT

    

   cT1-2

88/208 (42)

 

46/167 (28)

 

   cT3-4

78/177 (41)

 

40/128 (31)

 

   Missing

6/15 (40)

0.833d

3/13 (23)

0.488d

Nodal status before NACT

    

   cN0

41/106 (39)

 

14/75 (19)

 

   cN1

115/270 (43)

 

70/213 (33)

 

   Missing

11/24 (26)

0.488 d

5/20 (25)

0.020 d

Tumor size after NACT

    

   ypT0

32/90 (36)

 

25/74 (34)

 

   ypT1

67/169 (40)

 

40/133 (30)

 

   ypT2-4

68/141 (48)

0.125

24/101 (24)

0.325

Nodal status after NACT

    

   ypN0

76/197 (39)

 

43/149 (29)

 

   ypN1-3

91/203 (45)

0.205

46/159 (29)

0.989

ER status

    

   Negative

67/147 (46)

 

42/118 (36)

 

   Positive

100/253 (40)

0.237

47/190 (25)

0.041

PR status

    

   Negative

67/137 (49)

 

43/105 (41)

 

   Positive

100/263 (38)

0.036

46/203 (23)

0.001

HER2 status

    

   Negative

133/306 (43)

 

69/237 (29)

 

   Positive

34/94 (36)

0.210

20/71 (28)

0.878

Response to NACT

    

   Responderb

156/373 (42)

 

87/285 (31)

 

   Nonresponderc

11/27 (41)

0.912

2/23 (9)

0.026

Pathologic remission

    

   pCR

26/75 (35)

 

18/60 (30)

 

   No pCR

141/325 (43)

0.168

71/248 (29)

0.833

HER2-directed NACT a

    

   No

24/68 (35)

 

8/48 (17)

 

   Yes

10/26 (39)

0.775

12/23 (52)

0.002

  1. NACT, neoadjuvant systemic therapy. aOnly HER2-positive patients were taken into account. bpCR or partial response. cStable or progressive disease.
  2. dP value (χ2 test) not including missing data.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us